Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07799649) titled 'ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR' on Sept. 1.

Study Type: Observational

Primary Sponsor: The First Affiliated Hospital with Nanjing Medical University

Condition: Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma

Intervention: Diagnostic Test: Tumor-Informed ctDNA-MRD Monitoring

Recruitment Status: Not recruiting

Date of First Enrollment: September 2026

Target Sample Size: 150

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07799649

Disclaimer: Curated by HT Syndication....